Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC, Zhu J, Desai K, Kinsey E, Kao C, Lee YH, Pabla S, Labriola MK, Tran J, Dragnev KH, Tafe LJ, Dayyani F, Gupta RT, McCall S, George DJ, Glenn ST, Nesline MK, George S, Zibelman M, Morrison C, Ornstein MC, Zhang T. Brown LC, et al. Among authors: labriola mk. J Immunother Cancer. 2022 Oct;10(10):e005249. doi: 10.1136/jitc-2022-005249. J Immunother Cancer. 2022. PMID: 36252996 Free PMC article.
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C. Conroy JM, et al. Among authors: labriola m. J Immunother Cancer. 2019 Jan 24;7(1):18. doi: 10.1186/s40425-018-0489-5. J Immunother Cancer. 2019. PMID: 30678715 Free PMC article.
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C. Pabla S, et al. Among authors: labriola m. J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3. J Immunother Cancer. 2019. PMID: 30709424 Free PMC article.
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.
Zhang T, Pabla S, Lenzo FL, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Giamo V, Andreas J, Wang Y, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Gupta R, Zhu J, Labriola M, McCall S, George DJ, Ghatalia P, Dayyani F, Edwards R, Park MS, Singh R, Jacob R, George S, Xu B, Zibelman M, Kurzrock R, Morrison C. Zhang T, et al. Among authors: labriola m. Oncoimmunology. 2020 Jun 10;9(1):1773200. doi: 10.1080/2162402X.2020.1773200. Oncoimmunology. 2020. PMID: 32923131 Free PMC article.
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
Brown LC, Tucker MD, Sedhom R, Schwartz EB, Zhu J, Kao C, Labriola MK, Gupta RT, Marin D, Wu Y, Gupta S, Zhang T, Harrison MR, George DJ, Alva A, Antonarakis ES, Armstrong AJ. Brown LC, et al. Among authors: labriola mk. J Immunother Cancer. 2021 Mar;9(3):e001792. doi: 10.1136/jitc-2020-001792. J Immunother Cancer. 2021. PMID: 33653800 Free PMC article.
25 results